(12) United States Patent (10) Patent No.: US 9,353,359 B2 Sorek Et Al
Total Page:16
File Type:pdf, Size:1020Kb
US009353359B2 (12) United States Patent (10) Patent No.: US 9,353,359 B2 Sorek et al. (45) Date of Patent: May 31, 2016 (54) BACTERIAL ANTI-PHAGE DEFENSE OTHER PUBLICATIONS SYSTEMS Copeland et al. 2007; Complete sequence of Pseudomonus (71) Applicant: Yeda Research and Development Co. mendocinaymp. EMBL: ABP83335.* Ltd., Rehovot (IL) Lucas et al. 2008; Complete sequence of Acidithiobacillus fer rooxidans ATCC 53993. EMBL: ACH83539.1. (72) Inventors: Rotem Sorek, Rehovot (IL); Hila Kerfeld et al. 2009; Complete sequence of plasmid of Amonifex Sberro, Rehovot (IL): Azita Leavitt, degensii KC4, EMBL: ACX53253.1.* Rehovot (IL) Lee et al. 2006; Sequence analysis of two cryptic plasmids from Bifidobacterium longump.O10A and construction of a shuttle clon (73) Assignee: Yeda Research and Development Co. ing vector. Applied Environmental Microbiology 72:527-535. Ltd., Rehovot (IL) EMBL: ACD97784.1. Alignment Only Being Sent.* Chenoll et al. 2012; Safety assessment of strain Bifidobacterium (*) Notice: Subject to any disclaimer, the term of this longum CECT 7347, a probiotic able to reduce the toxicity and patent is extended or adjusted under 35 inflammatory potential of gliadin-derived peptides, based on pheno U.S.C. 154(b) by 0 days. typic traits, whole genome sequencing, and murine trials. EMBL: CCK35109.18 (21) Appl. No.: 14/140,793 PajonEMBL et al. Clife2010; The genome sequenceC of Bifidobacterium longumgu Schell et al. 2002; The genome sequence of Bifidobacterium longum (22) Filed: Dec. 26, 2013 reflects its Apato the R gastrointestinal tract. SS (65) Prior Publication Data 12-1427 EMBL: AAN25255.1. Alignment Only Being US 2014/O178353 A1 Jun. 26, 2014 Wardetal. 2010; The genome sequence of Bifidobacterium sp. Strain 12 1 47BFAA) EMBL: EFV37145.1.* Related U.S. Application Data DeBoy et al. 2008; Insights into plant cell wall degradation from the genome sequence of soil bacterium Cellvibrio japonicas. J. Bacteri (60) Provisional application No. 61/745,838, filed on Dec. ology. 190: 5455-5463. EMBL: ACE841 12.1. Alighnment Only 26, 2012. Being Sent.* s Larimaretal. 2006; Annotation of the draft genome assembly of delta (51) Int. Cl. proteobacterium MLMS-1, EMBL: EAT06598.* Score Search Results; Percent Identity Comparison of SEQ ID No. Yite 3.08: 3001 with 45 other 793 sequences. 3. p Q Score Search Results; Percent Identity Comparison of SEQ ID No. CI2N 9/12 (2006.01) 2773 with 45 other 793 sequences. 2015.* C07K I4/8 (2006.01) Makarova et al. “Defense Islands in Bacterial and Archaeal Genomes A61 K38/00 (2006.01) and Prediction of Novel Defense Systems”, Journal of Bacteriology, (52) U.S. Cl. 193(21):6039-6056, Nov. 2011. CPC .............. CI2N 9/22 (2013.01); C07K 14/8107 (2013.01); CI2N 9/1241 (2013.01); A61K * cited by examiner 38/00 (2013.01) (58) Field of Classification Search Primary Examiner — Karen Cochrane Carlson CPC ....................................................... CO7K 14/OO See application file for complete search history. (57) ABSTRACT An isolated polypeptide is disclosed comprising an amino (56) References Cited acid sequence selected from the group consisting of SEQID NOS: 2773-5544 and 11089-11094, wherein the polypeptide U.S. PATENT DOCUMENTS has antimicrobial activity. Uses thereof for treating microbial infections are also disclosed. 5,994,118 A 11/1999 Moineau et al. 7,169,911 B2 1/2007 Durmaz et al. 7.550,576 B2 6/2009 Klaenhammer et al. 10 Claims, 13 Drawing Sheets 7,754,868 B2 7/2010 Klaenhammer et al. (10 of 13 Drawing Sheet(s) Filed in Color) U.S. Patent US 9,353,359 B2 U.S. Patent May 31 9 2016 Sheet 2 of 13 US 9,353,359 B2 (seuopuolinusº)4 U.S. Patent May 31, 2016 Sheet 3 of 13 US 9,353,359 B2 89'943 s s U.S. Patent May 31, 2016 Sheet 4 of 13 US 9,353,359 B2 sorar tific U.S. Patent May 31, 2016 Sheet 5 of 13 US 9,353,359 B2 3#8888 §§§§§§§§ U.S. Patent May 31, 2016 Sheet 6 of 13 US 9,353,359 B2 esou?ândøeseuotuopnasa? U.S. Patent May 31, 2016 Sheet 7 of 13 US 9,353,359 B2 Geo@ U.S. Patent May 31, 2016 Sheet 8 of 13 US 9,353,359 B2 **********x*{#. ********@*$$ U.S. Patent May 31, 2016 Sheet 9 of 13 US 9,353,359 B2 U.S. Patent May 31, 2016 Sheet 10 of 13 US 9,353,359 B2 8 8 ''''''''''''''' 8x8x 838 era is x, 3e U.S. Patent May 31, 2016 Sheet 11 of 13 US 9,353,359 B2  90 Suojelus go equirM U.S. Patent US 9,353,359 B2 U.S. Patent May 31, 2016 Sheet 13 of 13 US 9,353,359 B2 o a o E co g s ba na C. c S. a. 8 ceog s S ca 5 E w wt is 3 es - E o t c c\ s d o 3 & a 2 to S 3 3 S 8 & 9 See eo) is OA. A Seuse, eo ui O A US 9,353,359 B2 1. 2 BACTERIAL ANT-PHAGE DEFENSE prokaryotic genomes (Shao et al., 2011). These systems (also SYSTEMS called TA modules), composed of a toxic gene and a neutral izing gene, were first suggested to function as plasmid addic RELATED APPLICATION tion molecules (Van Melderen and Saavedra De Bast, 2009: Wozniak and Waldor, 2009), but their prevalent existence on This application claims the benefit of priority under 35 chromosomes (Aizenman et al., 1996: Makarova et al., 2009: USC S 119(e) of U.S. Provisional Patent Application No. Shao et al., 2011) has led to the understanding that this is 61/745,838 filed Dec. 26, 2012, the contents of which are unlikely their major role. Accumulating evidence Suggest that incorporated herein by reference in their entirety. TA modules play pivotal roles in prokaryotic cellular biology 10 including programmed cell death (Hazan et al., 2004), stress GOVERNMENT INTERESTS response (Christensen et al., 2001), generation of persister cells (Schumacher et al., 2009), biofilm formation (Kimetal. Federally Sponsored Research 2009) and phage defense via abortive infection (Fineranet al., 15 2009; Hazan and Engelberg-Kulka, 2004: Koga et al., 2011; This invention was made with government Support under Pecota and Wood, 1996). AI082376 awarded by NIH. The government has certain The most prevalent kind of TA systems is type II systems, rights in the invention. where both toxin and antitoxin are proteins (as opposed to SEQUENCE LISTING STATEMENT types I and III where the antitoxin is a non-coding RNA (Fineran et al., 2009; Fozo et al.)). The two genes, which The ASCII file, entitled 57892SequenceListing..txt, created reside on the same operon, code for Small proteins and inhi on Nov. 11, 2013, comprising 20.497.456 bytes, submitted bition of the toxin is carried out through protein-protein inter concurrently with the filing of this application is incorporated action. As a rule, the toxin is a stable protein and the antitoxin herein by reference. is unstable and degrades rapidly by one of the housekeeping 25 bacterial proteases, usually Lon or Clplp (Aizenman et al., FIELD AND BACKGROUND OF THE 1996; Cherny and Gazit, 2004; Christensen et al., 2004; INVENTION Christensen et al., 2001; Christensen et al., 2003; Lehnherr and Yarmolinsky, 1995; Roberts et al., 1994; Van Melderenet The present invention, in some embodiments thereof, al., 1996). As a result, continuous production of the antitoxin relates to bacterial polypeptides that comprise toxin or anti 30 is required to prevent the toxins deleterious effects (Van toxin activity and, more particularly, but not exclusively, to Melderen and Saavedra De Bast, 2009). toxin-antitoxin pairs that may be used as bacterial anti-phage A number of reports demonstrate a role for type II TA defense systems. systems in phage resistance via an Abi mechanism: the exten Abroad array of food products, commodity chemicals, and sively studied MazEF system was shown to eliminate P1 biotechnology products are manufactured industrially by 35 phage infection (Hazan and Engelberg-Kulka, 2004), and the large-scale bacterial fermentation of various Substrates. recently identified RnlA toxin which is activated following Because enormous amounts of bacteria are being cultivated T4 phage infection degrades phage mRNAS (Koga et al., each day in large fermentation vats, bacteriophage contami 2011). Type I and Type IIITA systems (hok/sokand ToxIN, to nation can rapidly bring fermentations to a halt and cause respectively) were also shown to provide resistance against economic setbacks, and is therefore considered a serious 40 phages (Fineran et al., 2009; Pecota and Wood, 1996). How threat in these industries. The dairy fermentation industry has ever, based on their presence in bacterial defense islands, it openly acknowledged the problem of phage and has been was hypothesized that TA systems play a much wider role in working with academia and starter culture companies to phage defense (Makarova et al., 2011). develop defense strategies and systems to curtail the propa The usage of Abi Systems for biotech purposes, especially gation and evolution of phages for decades. 45 in protecting dairy industry bacteria from bacteriophages is To Survive in the face of perpetual phage attacks, bacteria disclosed in U.S. Pat. Nos. 7,754,868, 7,550,576, 7,169,911 have developed a variety of anti-phage defense systems (Lab and 5,994,118. rie et al., 2010; Sternand Sorek, 2011). These systems include To date, at least 12 families oftype IITA systems have been restriction enzymes that recognize and cleave foreign DNA described (Masuda et al., 2012; Shao et al., 2011). Members (King and Murray, 1994), abortive infection (Abi) mecha 50 of these families are widespread in bacterial and archaeal nisms that lead the bacterial cell, upon phage invasion, to genomes and undergo extensive horizontal gene transfer commit "suicide, thus protecting the colony against phage (Guglielmini et al., 2008: Makarova et al., 2009; Pandey and spread (Chopinet al., 2005); and the recently identified adap Gerdes, 2005: Shao et al., 2011).